John Deguzman, MD
Physical Medicine & Rehabilitation · Quincy, ILNPI 1376567354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novo Nordisk accounts for 62.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $425 and has fallen 59.3% since, to $173 in 2025.
Across 19 payments — averaging $40.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$481
- Scilex Pharmaceuticals Inc.$49
- Viiv Healthcare Company$43
- Kaleo, Inc.$38
- Kyowa Kirin, Inc.$26
- Recordati_rare_diseases_inc.$26
- plus $104 from 6 others
What the payments were for
- Food & beverage$767100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $481 |
| Scilex Pharmaceuticals Inc. | 1 | $49 |
| Viiv Healthcare Company | 2 | $43 |
| Kaleo, Inc. | 1 | $38 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Abbott | 1 | $22 |
| Organon | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Fidia Pharma USA Inc. | 1 | $14 |
| Novartis | 1 | $12 |
How this compares
$767 in reported general payments places this provider in the 80th percentile of 433 physical medicine & rehabilitation providers in Illinois.
See all physical medicine & rehabilitation providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 23 | $674 |
| Enoxaparin Sodium | 14 | $655 |
| Digoxin | 19 | $621 |
| Pantoprazole Sodium | 45 | $345 |
| Gabapentin | 21 | $302 |
| Atorvastatin Calcium | 52 | $260 |
| Metoprolol Succinate | 23 | $242 |
| Famotidine | 25 | $158 |
| Furosemide | 26 | $119 |
| ClopidogrelClopidogrel Bisulfate | 16 | $72 |
| Omeprazole | 12 | $68 |
| Lisinopril | 23 | $67 |
| Tamsulosin Hcl | 14 | $57 |
| Oxycodone Hcl | 14 | $56 |
| Amlodipine Besylate | 21 | $55 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Quincy
- Zachary McCormickChicago$290K
- Shivani GuptaOak Lawn$201K
- David SchneiderBarrington$30K
- Hugh McDermottMaywood$22K
- Prasanth KattaSycamore$19K
- Ravi KasiChicago$17K
- Steven KreisChicago$16K
- Henry GuanChicago$11K
- Ibrahim Usman-OyoweChicago$10K
- David RosaniaHinsdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.